Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A known ✓ | P28223 | 1/20 | 0.48 |
| ▸ | HTR2C known ✓ | P28335 | 1/20 | 0.48 |
| ▸ | HTR2B known ✓ | P41595 | 1/20 | 0.48 |
| ▸ | LARS1 | Q9P2J5 | 3/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL469480 | 0.99 | LARS1 (0.62) | LARS1HTR2AHTR2CHTR2B | |
| SCHEMBL5019535 | 0.99 | LARS1 (0.62) | LARS1HTR2AHTR2CHTR2B | |
| SCHEMBL16256481 | 0.89 | LARS1 (0.50) | LARS1HTR2AHTR2CHTR2B | |
| SCHEMBL16256486 | 0.88 | LARS1 (0.50) | LARS1 | |
| SCHEMBL16256485 | 0.88 | LARS1 (0.50) | LARS1 | |
| SCHEMBL13035543 | 0.87 | LARS1 (0.48) | LARS1 | |
| SCHEMBL455858 | 0.86 | LARS1 (0.49) | LARS1 | |
| SCHEMBL13035562 | 0.86 | LARS1 (0.47) | LARS1 | |
| Hydrochloric Acid SCHEMBL3446383 | 0.86 | LARS1 (0.61) | LARS1HTR2AHTR2CHTR2B | |
| SCHEMBL13035545 | 0.85 | LARS1 (0.47) | LARS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3251678-B1 | BENZOXABOROLE DERIVATIVES FOR TREATING BACTERIAL INFECTIONS | ANACOR PHARMACEUTICALS INC (US) | 2021-10-20 | — | — | EP | disclosed |
| US-11008345-B2 | Boron-containing small molecules | ANACOR PHARMACEUTICALS, INC. (US) | 2021-05-18 | — | — | US | disclosed |
| US-20190345173-A1 | BORON-CONTAINING SMALL MOLECULES | ANACOR PHARMACEUTICALS, LLC | 2019-11-14 | — | — | US | disclosed |
| US-20180016285-A1 | Boron-Containing Small Molecules | ANACOR PHARMACEUTICALS, LLC | 2018-01-18 | — | — | US | disclosed |
| US-20170355719-A1 | BORON-CONTAINING SMALL MOLECULES | ANACOR PHARMACEUTICALS, INC. | 2017-12-14 | — | — | US | disclosed |
| EP-3251678-A1 | BENZOXABOROLE DERIVATIVES FOR TREATING BACTERIAL INFECTIONS | Anacor Pharmaceuticals, Inc. (US) | 2017-12-06 | — | — | EP | disclosed |
| EP-2164331-B1 | BORON-CONTAINING SMALL MOLECULES | ANACOR PHARMACEUTICALS INC (US) | 2017-11-29 | — | — | EP | disclosed |
| US-9796735-B2 | Boron-containing small molecules | ANACOR PHARMACEUTICALS, INC. (US) | 2017-10-24 | — | — | US | disclosed |
| US-9751898-B2 | Boron-containing small molecules | ANACOR PHARMACEUTICALS, INC. (US) | 2017-09-05 | — | — | US | disclosed |
| EP-2613788-B1 | BENZOXABOROLE DERIVATIVES FOR TREATING BACTERIAL INFECTIONS | ANACOR PHARMACEUTICALS INC (US) | 2017-06-21 | — | — | EP | disclosed |
| US-20150133402-A1 | BORON-CONTAINING SMALL MOLECULES | ANACOR PHARMACEUTICALS, LLC | 2015-05-14 | — | — | US | disclosed |
| US-8895534-B2 | Boron containing small molecules | ANACOR PHARMACEUTICALS, INC. (US) | 2014-11-25 | — | — | US | disclosed |
| US-20140315860-A1 | BORON-CONTAINING SMALL MOLECULES | ANACOR PHARMACEUTICALS, INC. (US) | 2014-10-23 | — | — | US | disclosed |
| US-8703742-B2 | Boron-containing small molecules | ANACOR PHARMACEUTICALS, INC. (US) | 2014-04-22 | — | — | US | disclosed |
| EP-2613788-A2 | BORON-CONTAINING SMALL MOLECULES | Anacor Pharmaceuticals, Inc. (US) | 2013-07-17 | — | — | EP | disclosed |
| US-20120115813-A1 | BORON-CONTAINING SMALL MOLECULES | ANACOR PHARMACEUTICALS, INC. (US) | 2012-05-10 | — | — | US | disclosed |
| WO-2012033858-A2 | BORON-CONTAINING SMALL MOLECULES | ANACOR PHARMACEUTICALS, INC. (US) | 2012-03-15 | — | — | WO | disclosed |
| US-20100292504-A1 | BORON-CONTAINING SMALL MOLECULES | ANACOR PHARMACEUTICALS, INC. (US) | 2010-11-18 | — | — | US | disclosed |
| US-7816344-B2 | oxaboroles such as 3-[[(3S)-3-(aminomethyl)-1-hydroxy-3H-2,1-benzoxaborol-7-yl]oxy]propan-1-ol, useful for treating bacterial infections; microbiocides; antibiotics | ANACOR PHARMACEUTICALS, INC. (US) | 2010-10-19 | — | — | US | disclosed |
| US-20090227541-A1 | oxaboroles such as 3-[[(3S)-3-(aminomethyl)-1-hydroxy-3H-2,1-benzoxaborol-7-yl]oxy]propan-1-ol, useful for treating bacterial infections; microbiocides; antibiotics | ANACOR PHARMACEUTICALS, INC. (US) | 2009-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11008345-B2 | Boron-containing small molecules | BCL6B, BTD, BROX | HTR2A 4460/4885HTR2C 4664/4885HTR2B 1381/4885 |
| US-20100292504-A1 | BORON-CONTAINING SMALL MOLECULES | BCL6B, BLVRB, BCL6 | HTR2A 4869/4885HTR2C 4879/4885HTR2B 4714/4885 |
| US-20150133402-A1 | BORON-CONTAINING SMALL MOLECULES | BCL6B, BLVRB, BCL6 | HTR2A 4869/4885HTR2C 4879/4885HTR2B 4714/4885 |
| US-20120115813-A1 | BORON-CONTAINING SMALL MOLECULES | BCL6B, BTD, BROX | HTR2A 4460/4885HTR2C 4664/4885HTR2B 1381/4885 |
| US-20090227541-A1 | oxaboroles such as 3-[[(3S)-3-(aminomethyl)-1-hydroxy-3H-2,1-benzoxaborol-7-yl]oxy]propan-1-ol, useful for treating bacterial infections; microbiocides; antibiotics | OXA1L, TLR1, OXER1 | HTR2A 4392/4885HTR2C 4026/4885HTR2B 2479/4885 |
| US-20170355719-A1 | BORON-CONTAINING SMALL MOLECULES | BCL6B, BTD, BROX | HTR2A 4460/4885HTR2C 4664/4885HTR2B 1381/4885 |
| US-20180016285-A1 | Boron-Containing Small Molecules | BCL6B, BLVRB, BCL6 | HTR2A 4869/4885HTR2C 4879/4885HTR2B 4714/4885 |
| US-20190345173-A1 | BORON-CONTAINING SMALL MOLECULES | BCL6B, BTD, BROX | HTR2A 4460/4885HTR2C 4664/4885HTR2B 1381/4885 |
| US-20140315860-A1 | BORON-CONTAINING SMALL MOLECULES | BCL6B, BTD, BROX | HTR2A 4460/4885HTR2C 4664/4885HTR2B 1381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.